TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Acrux ( (AU:ACR) ) just unveiled an update.
Acrux Ltd announced a change in the director’s interest, with Tim Oldham acquiring 2,866,719 unlisted rights, as approved at the company’s AGM on November 25, 2025. This change reflects a strategic move to align the director’s interests with the company’s long-term goals, potentially impacting stakeholder confidence and Acrux’s market positioning.
The most recent analyst rating on (AU:ACR) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Acrux stock, see the AU:ACR Stock Forecast page.
More about Acrux
Acrux Ltd operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery solutions. The company primarily offers products that enhance the delivery of medications through the skin, catering to various therapeutic areas and aiming to improve patient outcomes.
Average Trading Volume: 318,326
Technical Sentiment Signal: Sell
Current Market Cap: A$5.75M
For an in-depth examination of ACR stock, go to TipRanks’ Overview page.